Lynx1 Capital Management LP Passage Bio, Inc. Transaction History
Lynx1 Capital Management LP
- $270 Million
- Q1 2025
A detailed history of Lynx1 Capital Management LP transactions in Passage Bio, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 9,256,953 shares of PASG stock, worth $53.2 Million. This represents 1.2% of its overall portfolio holdings.
Number of Shares
9,256,953
Previous 9,256,953
-0.0%
Holding current value
$53.2 Million
Previous $5.28 Million
38.61%
% of portfolio
1.2%
Previous 2.05%
Shares
12 transactions
Others Institutions Holding PASG
# of Institutions
44Shares Held
36.4MCall Options Held
50.3KPut Options Held
0-
Orbimed Advisors LLC San Diego, CA7.03MShares$40.4 Million0.08% of portfolio
-
Vestal Point Capital, LP New York, NY6.1MShares$35.1 Million0.15% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY2.5MShares$14.4 Million1.97% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.46MShares$14.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.07MShares$11.9 Million0.0% of portfolio
About Passage BIO, Inc.
- Ticker PASG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,463,200
- Market Cap $313M
- Description
- Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...